Tolerability, Safety, Immunogenicity and Pharmacokinetic of JS005
1 clinical trials · Condition
◉ Watch Tolerability, Safety, Immunogenicity and Pharmacokinetic of JS005
| Record | Firm | Date |
|---|---|---|
| Phase I Study of Comparing Single Dose JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) With Placebo in Tolerability, Safety, Immunogenicity and Pharmacokinetic in Healthy Volunteers (NCT04220073) | Shanghai Junshi Bioscience Co., Ltd. | 2020-05-17 |
Track Tolerability, Safety, Immunogenicity and Pharmacokinetic of JS005 automatically
Every clearance here is in the API, with alerts when new ones post.